Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intetumumab
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Intetumumab is a fully human monoclonal antibody that targets the αv integrin family, specifically binding to and blocking both integrin alphaVbeta3 (αvβ3) and integrin alphaVbeta5 (αvβ5). By inhibiting these integrins, intetumumab disrupts integrin-mediated tumor angiogenesis and tumor growth. This antiangiogenic effect results in the inhibition of cell adhesion, migration, proliferation, and invasion of both tumor and endothelial cells. Intetumumab was developed primarily for oncology indications such as malignant melanoma and prostate cancer but development has been discontinued. The drug was originally developed by Centocor (now Janssen Biotech), with later involvement from Janssen-Cilag[1][2][3][4].
- Other names
- intetumumab
02
Targets
αVβ1 (Integrin alpha-V beta-1)αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)αVβ6 (Integrin αVβ6)
Beyond the preview
Go deeper on intetumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intetumumab.